EMA Authorised: Rivaroxaban Koanaa (rivaroxaban) — Koanaa Healthcare GmbH

View source ↗

Summary

The European Medicines Agency authorised Koanaa Healthcare GmbH's rivaroxaban product, Koanaa, for indications including venous thromboembolism, pulmonary embol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism
• Stroke
• Venous Thromboembolism
• Venous Thrombosis

Drugs mentioned

• Rivaroxaban Koanaa (rivaroxaban)

Snippet

Status: Authorised. Therapeutic area: Venous Thromboembolism;Pulmonary Embolism;Venous Thrombosis;Stroke;Embolism. MAH: Koanaa Healthcare GmbH. Decision date: 21/11/2025